Patent 7314936 was granted and assigned to Eisai on January, 2008 by the United States Patent and Trademark Office.
The present invention provides compounds having formula (I), wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally